Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication

Endocrine

Volumn 49, Issue 1, 2015, Pages 274-278

  Marotta, Vincenzo ^a   Di Somma, Carolina ^a   Rubino, Manila ^a   Sciammarella, Concetta ^a   Del Prete, Michela ^a   Marciello, Francesca ^a   Ramundo, Valeria ^a   Circelli, Luisa ^b   Buonomano, Pasqualina ^a   Modica, Roberta ^a   Vitale, Mario ^c   Colao, Annamaria ^a   Faggiano, Antongiulio ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CINACALCET; PARATHYROID HORMONE;

ADULT; BLOOD; BONE DENSITY; FEMALE; FOLLOW UP; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; MALE; PHYSIOLOGY; SECRETION (PROCESS); TREATMENT OUTCOME;

ADULT; BONE DENSITY; CALCIMIMETIC AGENTS; CALCIUM; CINACALCET HYDROCHLORIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; MALE; PARATHYROID HORMONE; TREATMENT OUTCOME;

EID: 84939879222     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0381-0     Document Type: Letter

References (18)

1. J.P. Bilezikian, M.L. Brandi, M. Rubin, S.J. Silverberg, Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J. Intern. Med. 257(1), 6–17 (2005). doi:10.1111/j.1365-2796.2004.01422.x
2. S.J. Silverberg, E. Shane, T.P. Jacobs, E. Siris, J.P. Bilezikian, A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 341(17), 1249–1255 (1999). doi:10.1056/NEJM199910213411701
3. M.R. Rubin, J.P. Bilezikian, D.J. McMahon, T. Jacobs, E. Shane, E. Siris, J. Udesky, S.J. Silverberg, The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J. Clin. Endocrinol. Metab. 93(9), 3462–3470 (2008). doi:10.1210/jc.2007-1215
4. R. Eastell, A. Arnold, M.L. Brandi, E.M. Brown, P. D’Amour, D.A. Hanley, D.S. Rao, M.R. Rubin, D. Goltzman, S.J. Silverberg, S.J. Marx, M. Peacock, L. Mosekilde, R. Bouillon, E.M. Lewiecki, Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 340–350 (2009). doi:10.1210/jc.2008-1758
5. J.P. Bilezikian, A.A. Khan, J.T. Potts Jr, Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 335–339 (2009). doi:10.1210/jc.2008-1763
6. E.F. Nemeth, W.H. Heaton, M. Miller, J. Fox, M.F. Balandrin, B.C. Van Wagenen, M. Colloton, W. Karbon, J. Scherrer, E. Shatzen, G. Rishton, S. Scully, M. Qi, R. Harris, D. Lacey, D. Martin, Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 308(2), 627–635 (2004). doi:10.1124/jpet.103.057273
7. C. Valle, M. Rodriguez, R. Santamaria, Y. Almaden, M.E. Rodriguez, S. Canadillas, A. Martin-Malo, P. Aljama, Cinacalcet reduces the set point of the PTH-calcium curve. J. Am. Soc. Nephrol. 19(12), 2430–2436 (2008). doi:10.1681/ASN.2007121320
8. N. Verheyen, S. Pilz, K. Eller, K. Kienreich, A. Fahrleitner-Pammer, B. Pieske, E. Ritz, A. Tomaschitz, Cinacalcet hydrochloride for the treatment of hyperparathyroidism. Expert Opin. Pharmacother. 14(6), 793–806 (2013). doi:10.1517/14656566.2013.777041
9. M.H. Gault, L.L. Longerich, J.D. Harnett, C. Wesolowski, Predicting glomerular function from adjusted serum creatinine. Nephron 62(3), 249–256 (1992)
10. H.K. Genant, C.Y. Wu, C. van Kuijk, M.C. Nevitt, Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8(9), 1137–1148 (1993). doi:10.1002/jbmr.5650080915
11. A.A. Khan, J.P. Bilezikian, A.W. Kung, M.M. Ahmed, S.J. Dubois, A.Y. Ho, D. Schussheim, M.R. Rubin, A.M. Shaikh, S.J. Silverberg, T.I. Standish, Z. Syed, Z.A. Syed, Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89(7), 3319–3325 (2004). doi:10.1210/jc.2003-03090889/7/3319
12. A. Khan, A. Grey, D. Shoback, Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 373–381 (2009). doi:10.1210/jc.2008-1762
13. M. Peacock, J.P. Bilezikian, M.A. Bolognese, M. Borofsky, S. Scumpia, L.R. Sterling, S. Cheng, D. Shoback, Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J. Clin. Endocrinol. Metab. 96(1), E9–E18 (2011). doi:10.1210/jc.2010-1221
14. M.L. Brandi, R.F. Gagel, A. Angeli, J.P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R.G. Gheri, A. Libroia, C.J. Lips, G. Lombardi, M. Mannelli, F. Pacini, B.A. Ponder, F. Raue, B. Skogseid, G. Tamburrano, R.V. Thakker, N.W. Thompson, P. Tomassetti, F. Tonelli, S.A. Wells Jr, S.J. Marx, Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86(12), 5658–5671 (2001). doi:10.1210/jcem.86.12.8070
15. N. Yu, G.P. Leese, D. Smith, P.T. Donnan, The natural history of treated and untreated primary hyperparathyroidism: the parathyroid epidemiology and audit research study. QJM 104(6), 513–521 (2011). doi:10.1093/qjmed/hcq261
16. S. Corbetta, G. Mantovani, A. Lania, S. Borgato, L. Vicentini, E. Beretta, G. Faglia, A.M. Di Blasio, A. Spada, Calcium-sensing receptor expression and signalling in human parathyroid adenomas and primary hyperplasia. Clin Endocrinol 52(3), 339–348 (2000)
17. J. Gogusev, P. Duchambon, B. Hory, M. Giovannini, Y. Goureau, E. Sarfati, T.B. Drueke, Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 51(1), 328–336 (1997)
18. C.A. Frolik, E.C. Black, R.L. Cain, J.H. Satterwhite, P.L. Brown-Augsburger, M. Sato, J.M. Hock, Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33(3), 372–379 (2003)